EYEG Quote, Trading Chart, Eyegate Pharmaceuticals Inc.
home / stock / eyeg / eyeg quote
$4.43 Last:
-2.21% Change Percent:
$4.5 Open:
$4.43 Previous Close:
$4.535 High:
$4.23 Low:
23,852 Volume:
06/21/2021 04:42:52 am Last Trade Date Time:
Quotes are delayed by 15 to 20 minutes.
EYEG Last Five Trading Days
| Stock Date | Open Price | Close Price | High | Low | Volume |
|---|---|---|---|---|---|
| 2021-06-21 | 4.5 | 4.43 | 4.535 | 4.23 | 23,852 |
| 2021-06-18 | 4.48 | 4.53 | 4.53 | 4.38 | 33,926 |
| 2021-06-17 | 4.3881 | 4.51 | 4.52 | 4.3362 | 25,337 |
| 2021-06-16 | 4.31 | 4.45 | 4.45 | 4.25 | 24,017 |
| 2021-06-15 | 4.7 | 4.35 | 4.74 | 4.26 | 35,008 |
| 2021-06-14 | 4.82 | 4.74 | 4.9999 | 4.5301 | 77,158 |
| 2021-06-11 | 4.6 | 4.49 | 4.6 | 4.41 | 15,527 |
| 2021-06-10 | 4.42 | 4.56 | 4.56 | 4.42 | 10,634 |
| 2021-06-09 | 4.4 | 4.44 | 4.6 | 4.4 | 22,096 |
| 2021-06-08 | 4.36 | 4.3831 | 4.87 | 4.35 | 43,420 |
| 2021-06-07 | 4.33 | 4.4 | 4.5793 | 4.32 | 17,831 |
| 2021-06-04 | 4.19 | 4.38 | 4.38 | 4.19 | 10,959 |
| 2021-06-03 | 4.3 | 4.26 | 4.36 | 4.14 | 11,580 |
| 2021-06-02 | 4.32 | 4.38 | 4.48 | 4.32 | 24,327 |
| 2021-06-01 | 4.56 | 4.24 | 4.74 | 4.2 | 61,634 |
| 2021-05-31 | 4.36 | 4.39 | 4.45 | 4.28 | 8,283 |
| 2021-05-28 | 4.36 | 4.39 | 4.45 | 4.28 | 7,880 |
| 2021-05-27 | 4.26 | 4.2 | 4.39 | 4.2 | 9,607 |
| 2021-05-26 | 4.54 | 4.39 | 4.625 | 4.2 | 30,128 |
| 2021-05-25 | 5.04 | 4.57 | 5.05 | 4.48 | 60,033 |
Eyegate Pharmaceuticals Inc. Company Name:
EYEG Stock Symbol:
NASDAQ Market:
Eyegate Pharmaceuticals Inc. Website:
News, Short Squeeze, Breakout and More Instantly...
-
- Proof-of-concept study conducted in Austria- -Topline data expected in Q4 2021- WALTHAM, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing and c...
-
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investors! We’re back at it again with a look at the biggest pre-market stock movers for Tuesday. Source: Shutterstock Chinese education stocks are on the move today and we’re all still s...
-
- PP-001: proof-of-concept study in Austria for dry eye patients expected to initiate in Q3:21; U.S. IND submission planned in Q4:21- -OBG: U.S. IND submission and initiation of Phase 2 dry eye study is planned in Q4:21; proof-of-concept study for persistent epithelial defects e...